NCT05560464View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 14, 2022

Primary Completion Date

July 24, 2023

Study Completion Date

July 24, 2023

Conditions
Pain
Interventions
DRUG

VX-548

Tablets for oral administration.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33136

Division of Clinical Pharmacology, University of Miami, Miami

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY